688235 百济神州
已收盘 04-30 15:00:00
资讯
新帖
简况
百济神州首次全年盈利背后：累计亏损超600亿元，大单品依赖与地缘政治隐忧｜财报异动透视镜
华夏时报网 · 05-01
百济神州首次全年盈利背后：累计亏损超600亿元，大单品依赖与地缘政治隐忧｜财报异动透视镜
百济神州：公司有望获得最高19亿美元里程碑款项及销售额分层特许权使用费
美股速递 · 04-30
百济神州：公司有望获得最高19亿美元里程碑款项及销售额分层特许权使用费
华晖健康与百济神州就创新肿瘤药物Hh160达成全球独家选择权、许可及合作协议
美股速递 · 04-30
华晖健康与百济神州就创新肿瘤药物Hh160达成全球独家选择权、许可及合作协议
盈利不足两月，百济神州豪掷20亿美元押注三抗
21世纪经济报道 · 04-28
盈利不足两月，百济神州豪掷20亿美元押注三抗
百济神州(06160)与华辉安健签订《合作协议》引进三特异性创新药全球独家开发权益
智通财经 · 04-27
百济神州(06160)与华辉安健签订《合作协议》引进三特异性创新药全球独家开发权益
每周股票复盘：百济神州（688235）将发布2026年一季报
证券之星 · 04-26
每周股票复盘：百济神州（688235）将发布2026年一季报
百济神州：公司严格执行《企业会计准则》和各项具体会计准则、企业会计准则应用指南、企业会计准则解释及其他相关规定
证券日报 · 04-20
百济神州：公司严格执行《企业会计准则》和各项具体会计准则、企业会计准则应用指南、企业会计准则解释及其他相关规定
每周股票复盘：百济神州（688235）2025年营收增40.46%
证券之星 · 04-19
每周股票复盘：百济神州（688235）2025年营收增40.46%
百济神州（688235）披露提名董事及拟调整董事会专门委员会组成公告，4月17日股价下跌4.08%
证券之星 · 04-17
百济神州（688235）披露提名董事及拟调整董事会专门委员会组成公告，4月17日股价下跌4.08%
百济神州（688235）2025年年报简析：营收净利润同比双双增长，盈利能力上升
证券之星 · 04-16
百济神州（688235）2025年年报简析：营收净利润同比双双增长，盈利能力上升
2025年A股药企薪酬：药明康德李革年薪3998万，百济神州人均薪酬94万
红星资本局 · 04-15
2025年A股药企薪酬：药明康德李革年薪3998万，百济神州人均薪酬94万
百济神州(688235)3月31日股东户数3.52万户，较上期增加6.53%
证券之星 · 04-15
百济神州(688235)3月31日股东户数3.52万户，较上期增加6.53%
百济神州年营收382亿：净利14.6亿 安进与Baker是核心股东
雷递网 · 04-15
百济神州年营收382亿：净利14.6亿 安进与Baker是核心股东
百济神州(688235.SH)发布2025年度业绩，扭亏为盈至14.61亿元
智通财经 · 04-14
百济神州(688235.SH)发布2025年度业绩，扭亏为盈至14.61亿元
百济神州安泰适在中国获得上市许可
南方财经网 · 04-10
百济神州安泰适在中国获得上市许可
百济神州(06160)授出合共1.77万股美国存托股份受限制股份单位
智通财经网 · 04-08
百济神州(06160)授出合共1.77万股美国存托股份受限制股份单位
每周股票复盘：百济神州（688235）2025年盈利2.87亿美元
证券之星 · 03-29
每周股票复盘：百济神州（688235）2025年盈利2.87亿美元
百济神州（688235）披露续聘2026年度审计机构公告，3月25日股价下跌0.43%
证券之星 · 03-25
百济神州（688235）披露续聘2026年度审计机构公告，3月25日股价下跌0.43%
百济神州：2025年净利润2.87亿美元
每日经济新闻 · 03-25
百济神州：2025年净利润2.87亿美元
百济神州跌5.30%，浦银国际证券二周前给出“买入”评级，目标价236.00元
证券之星 · 03-23
百济神州跌5.30%，浦银国际证券二周前给出“买入”评级，目标价236.00元
公司概况
公司名称：
百济神州有限公司
所属行业：
医药制造业
上市日期：
2021-12-15
主营业务：
百济神州有限公司的主营业务是研究、开发、生产以及商业化创新型药物。公司的主要产品是抗肿瘤类药物。
发行价格：
192.60
{"stockData":{"symbol":"688235","market":"SH","secType":"STK","nameCN":"百济神州","latestPrice":234.8,"timestamp":1777532400000,"preClose":236.31,"halted":0,"volume":2536115,"delay":0,"changeRate":-0.0064,"floatShares":114999999,"shares":1542000000,"eps":5.1245,"marketStatus":"已收盘","change":-1.51,"latestTime":"04-30 15:00:00","open":236,"high":237.97,"low":232.05,"amount":595000000,"amplitude":0.0251,"askPrice":234.8,"askSize":23,"bidPrice":234.79,"bidSize":5,"shortable":0,"etf":0,"ttmEps":5.1245,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1778031000000},"marketStatusCode":5,"adr":0,"adjPreClose":236.31,"symbolType":"stock_kcb","openAndCloseTimeList":[[1777512600000,1777519800000],[1777525200000,1777532400000]],"highLimit":259.94,"lowLimit":212.68,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1541583805,"isCdr":false,"pbRate":11.81,"roa":"--","peRate":45.819104,"roe":"5.33%","epsLYR":1.03,"committee":-0.15,"marketValue":361964000000,"turnoverRate":0.022,"status":1,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-05-06。","afterMarket":{"amount":0,"volume":0,"close":234.8,"buyVolume":15319,"sellVolume":0,"time":1777534437559,"indexStatus":"已收盘 04-30 15:30:00","preClose":236.31},"hkstockBrief":{"symbol":"06160","market":"HK","secType":"STK","nameCN":"百济神州","latestPrice":176.7,"timestamp":1777949046794,"preClose":176.7,"halted":0,"volume":382539,"delay":0,"premium":"-34.40"},"floatMarketCap":27015000000},"requestUrl":"/m/hq/s/688235/wiki","defaultTab":"wiki","newsList":[{"id":"2632618011","title":"百济神州首次全年盈利背后：累计亏损超600亿元，大单品依赖与地缘政治隐忧｜财报异动透视镜","url":"https://stock-news.laohu8.com/highlight/detail?id=2632618011","media":"华夏时报网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632618011?lang=zh_cn&edition=full","pubTime":"2026-05-01 16:32","pubTimestamp":1777624341,"startTime":"0","endTime":"0","summary":"这家中国抗癌药明星企业交出了史上首份盈利年报，但高达612亿元的累计未弥补亏损、对单一产品的深度依赖，以及愈演愈烈的中美药品定价博弈，令其“全球肿瘤创新公司”的故事蒙上阴影。对百济神州而言，2025年本应是举杯相庆的一年。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605013727283548.html","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605013727283548.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["06160","ONC","688235"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197339952","title":"百济神州：公司有望获得最高19亿美元里程碑款项及销售额分层特许权使用费","url":"https://stock-news.laohu8.com/highlight/detail?id=1197339952","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1197339952?lang=zh_cn&edition=full","pubTime":"2026-04-30 16:28","pubTimestamp":1777537708,"startTime":"0","endTime":"0","summary":"百济神州宣布，根据合作协议条款，公司具备资格获取累计最高达19亿美元的里程碑付款。此外，协议还约定将基于产品净销售额按阶梯比例收取特许权使用费。\n此次财务安排体现了合作方对公司研发成果的高度认可，也为企业未来现金流提供了有力支撑。分层 royalties 机制将确保公司在商业化阶段持续获得收益回报。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688235","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123643271","title":"华晖健康与百济神州就创新肿瘤药物Hh160达成全球独家选择权、许可及合作协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1123643271","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1123643271?lang=zh_cn&edition=full","pubTime":"2026-04-30 16:28","pubTimestamp":1777537705,"startTime":"0","endTime":"0","summary":"华晖健康与百济神州宣布，双方已就创新肿瘤药物Hh160签署全球独家选择权、许可及合作协议。该协议的达成标志着两家公司在肿瘤治疗领域的战略合作进入新阶段。根据协议条款，百济神州将获得Hh160在全球范围内的独家开发、生产和商业化权利。此次合作将整合华晖健康在创新药物研发方面的优势与百济神州在全球临床开发和商业化运营的丰富经验。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","688235"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630323200","title":"盈利不足两月，百济神州豪掷20亿美元押注三抗","url":"https://stock-news.laohu8.com/highlight/detail?id=2630323200","media":"21世纪经济报道","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630323200?lang=zh_cn&edition=full","pubTime":"2026-04-28 11:23","pubTimestamp":1777346580,"startTime":"0","endTime":"0","summary":"21世纪经济报道记者季媛媛从“年年巨亏”到“首年盈利”，百济神州用了十五年。当这面象征盈利喜悦的旗帜刚刚升起，百济神州在此节点选择花费重金与一家biotech企业达成BD（授权交易）合作。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604283721914325.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604283721914325.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1969619763.USD","06160","BK4139","LU1251922891.USD","BK1583","LU1303224171.USD","LU0307460666.USD","BK1588","ONC","BK4588","BK0239","688235","LU2328871848.SGD","LU1770034418.SGD","BK1161","LU1719994722.HKD","BK4526","BK1500","LU0588546209.SGD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630393872","title":"百济神州(06160)与华辉安健签订《合作协议》引进三特异性创新药全球独家开发权益","url":"https://stock-news.laohu8.com/highlight/detail?id=2630393872","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630393872?lang=zh_cn&edition=full","pubTime":"2026-04-27 19:03","pubTimestamp":1777287828,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百济神州 发布公告，2026 年 4 月 24 日，公司全资子公司百济神州广州与华辉安健签订了一份《合作协议》。此外，华辉安健同意在相关里程碑达成后，向百济神州广州支付其被百济神州广州授予相关知识产权许可的对价。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1434590.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1588","LU1719994722.HKD","BK4526","LU1303224171.USD","159992","688235","BK4585","BK1574","BK0239","LU2328871848.SGD","BK1161","LU1251922891.USD","06160","ONC","BK4139","BK1583","BK4588","LU0307460666.USD","BK1500","LU0588546209.SGD","LU1770034418.SGD","LU1969619763.USD","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630380141","title":"每周股票复盘：百济神州（688235）将发布2026年一季报","url":"https://stock-news.laohu8.com/highlight/detail?id=2630380141","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630380141?lang=zh_cn&edition=full","pubTime":"2026-04-26 02:43","pubTimestamp":1777142589,"startTime":"0","endTime":"0","summary":"截至2026年4月24日收盘，百济神州报收于234.86元，较上周的246.5元下跌4.72%。本周，百济神州4月20日盘中最高价报250.18元。本周关注点公司公告汇总：百济神州将于2026年5月6日发布第一季度未经审核财务业绩。公司公告汇总港股公告：2026年第一季度财务业绩公布日期及审计委员会行动通告百济神州有限公司将于2026年5月6日发布截至2026年3月31日的第一季度未经审核财务业绩，并由董事会审计委员会审阅及批准。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042600000984.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1588","BK1583","LU0588546209.SGD","LU1251922891.USD","LU1770034418.SGD","LU0307460666.USD","688235","LU1969619763.USD","BK1500","LU1303224171.USD","LU2328871848.SGD","BK1161","LU1719994722.HKD","06160","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628093746","title":"百济神州：公司严格执行《企业会计准则》和各项具体会计准则、企业会计准则应用指南、企业会计准则解释及其他相关规定","url":"https://stock-news.laohu8.com/highlight/detail?id=2628093746","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628093746?lang=zh_cn&edition=full","pubTime":"2026-04-20 17:30","pubTimestamp":1776677400,"startTime":"0","endTime":"0","summary":"证券日报网讯4月20日，百济神州在互动平台回答投资者提问时表示，公司已在2026年4月15日披露的《百济神州2025年年度报告》中详细披露报告期内的公司营业收入、销售费用、管理费用的变动原因。公司严格执行《企业会计准则》和各项具体会计准则、企业会计准则应用指南、企业会计准则解释及其他相关规定，财务数据客观公允反映公司财务状况和生产经营成果，不存在跨期结转成本费用的情形。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604203710742828.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","BK4139","688235","LU1303224171.USD","BK4585","LU2328871848.SGD","BK1583","BK4526","LU1770034418.SGD","LU0307460666.USD","LU1719994722.HKD","LU1969619763.USD","BK4588","06160","BK1588","LU1251922891.USD","LU0588546209.SGD","BK1500","ONC","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628756468","title":"每周股票复盘：百济神州（688235）2025年营收增40.46%","url":"https://stock-news.laohu8.com/highlight/detail?id=2628756468","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628756468?lang=zh_cn&edition=full","pubTime":"2026-04-19 01:52","pubTimestamp":1776534727,"startTime":"0","endTime":"0","summary":"截至2026年4月17日收盘，百济神州报收于246.5元，较上周的244.12元上涨0.97%。本周，百济神州4月15日盘中最高价报259.0元。业绩披露要点百济神州2025年实现主营收入382.25亿元，同比增长40.46%；归母净利润14.61亿元，同比增长129.34%；扣非净利润14.2亿元，同比增长126.39%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041900000593.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688235","06160"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628274603","title":"百济神州（688235）披露提名董事及拟调整董事会专门委员会组成公告，4月17日股价下跌4.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2628274603","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628274603?lang=zh_cn&edition=full","pubTime":"2026-04-17 17:17","pubTimestamp":1776417477,"startTime":"0","endTime":"0","summary":"截至2026年4月17日收盘，百济神州报收于246.5元，较前一交易日下跌4.08%，最新总市值为3799.6亿元。该股当日开盘255.0元，最高255.0元，最低245.2元，成交额达11.23亿元，换手率为3.94%。百济神州有限公司于2026年4月17日发布《关于提名董事及拟调整董事会专门委员会组成的公告》。其中Baker博士、Mooney女士和Sawyers博士为新提名人，分别拟任非执行董事和独立非执行董事。四位现任独立非执行董事将不参与重选。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041700032753.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1719994722.HKD","LU1770034418.SGD","LU0307460666.USD","BK1583","LU1251922891.USD","LU1969619763.USD","06160","LU2328871848.SGD","BK1500","BK0239","BK1588","LU1303224171.USD","BK1161","688235","LU0588546209.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627253713","title":"百济神州（688235）2025年年报简析：营收净利润同比双双增长，盈利能力上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2627253713","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627253713?lang=zh_cn&edition=full","pubTime":"2026-04-16 06:06","pubTimestamp":1776290795,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期百济神州发布2025年年报。截至本报告期末，公司营业总收入382.25亿元，同比上升40.46%，归母净利润14.61亿元，同比上升129.34%。本报告期百济神州盈利能力上升，毛利率同比增幅3.76%，净利率同比增幅120.89%。该数据高于大多数分析师的预期，此前分析师普遍预期2025年净利润为盈利14.22亿元左右。公司在2025财年首次实现GP净利润和非GP净利润。2025年，我们的经营活动产生的净现金为11亿美元，自由现金流为正。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041600004781.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688235","06160"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627328932","title":"2025年A股药企薪酬：药明康德李革年薪3998万，百济神州人均薪酬94万","url":"https://stock-news.laohu8.com/highlight/detail?id=2627328932","media":"红星资本局","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627328932?lang=zh_cn&edition=full","pubTime":"2026-04-15 19:00","pubTimestamp":1776250843,"startTime":"0","endTime":"0","summary":"红星资本局4月15日消息，随着年报季到来，A股已有超120家医药企业披露了2025年经营业绩，其员工薪酬也受到关注。红星资本局根据企业年报、数据统计发现，药明康德（603259.SH；2359.HK）创始人李革以3998万元的年薪暂列药企管理层第一，较第二名高出1800多万元，其连续位列A股管理层薪酬榜首。人均薪酬方面，百济神州达到94.63万元，位居第一。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604153706121691.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1969619763.USD","LU2125910500.SGD","BK4139","LU1997245094.SGD","LU1046422090.SGD","159982","LU2242644610.SGD","LU0051755006.USD","LU1979443071.USD","ONC","LU2328871848.SGD","LU0307460666.USD","LU0417516902.SGD","LU2039709279.SGD","LU0516422366.SGD","LU0039217434.USD","LU0456842615.SGD","LU0320764599.SGD","LU2488822045.USD","06160","LU0856984785.SGD","LU1242518857.USD","LU1770034418.SGD","LU1720050803.USD","LU1934453819.USD","LU0327786744.USD","SG9999002562.SGD","LU0348825331.USD","LU1808992512.USD","BK4588","BK1576","LU2495084118.USD","BK4526","603259","02359","399300","LU0043850808.USD","02269","LU0708995583.HKD","LU1997244956.HKD","LU0588546209.SGD","LU1688375341.USD","688235","LU3063872942.SGD","IE00B0JY6N72.USD","LU1719994722.HKD","BK1583","BK1610","BK1589","LU0572944931.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627407195","title":"百济神州(688235)3月31日股东户数3.52万户，较上期增加6.53%","url":"https://stock-news.laohu8.com/highlight/detail?id=2627407195","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627407195?lang=zh_cn&edition=full","pubTime":"2026-04-15 17:13","pubTimestamp":1776244398,"startTime":"0","endTime":"0","summary":"证券之星消息，近日百济神州披露，截至2026年3月31日公司股东户数为3.52万户，较12月31日增加2161.0户，增幅为6.53%。在化学制药行业个股中，百济神州股东户数高于行业平均水平，截至3月31日，化学制药行业平均股东户数为3.52万户。从股价来看，2025年12月31日至2026年3月31日，百济神州区间跌幅为13.03%，在此期间股东户数增加2161.0户，增幅为6.53%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041500030820.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1719994722.HKD","BK1500","LU2328871848.SGD","688235","LU0307460666.USD","LU1251922891.USD","LU1969619763.USD","LU1303224171.USD","06160","BK0239","BK1588","LU1770034418.SGD","BK1583","BK1161","LU0588546209.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627415479","title":"百济神州年营收382亿：净利14.6亿 安进与Baker是核心股东","url":"https://stock-news.laohu8.com/highlight/detail?id=2627415479","media":"雷递网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627415479?lang=zh_cn&edition=full","pubTime":"2026-04-15 09:52","pubTimestamp":1776217938,"startTime":"0","endTime":"0","summary":"百济神州有限公司（公司代码：688235 公司简称：百济神州）日前发布截至2025年12月31日的财报。财报显示，百济神州2025年营收为382.25亿，较上年同期的272亿增长40.46%；","market":"hk","thumbnail":"https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260415/6391184353468399959612189.jpeg","type":0,"news_type":0,"thumbnails":["https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260415/6391184353468399959612189.jpeg"],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.leinews.com/n33283/detail.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"leinews_highlight","symbols":["06160","ONC","688235","AMGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627445534","title":"百济神州(688235.SH)发布2025年度业绩，扭亏为盈至14.61亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2627445534","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627445534?lang=zh_cn&edition=full","pubTime":"2026-04-14 21:39","pubTimestamp":1776173982,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百济神州 发布2025年年度报告，报告期内，公司实现营业收入382.25亿元，同比增长40.46%。实现归属于上市公司股东的净利润14.61亿元。2023年1月，根据两项3期试验结果，百悦泽获批用于治疗初治和复发性CLL或SLL成年患者。2024年3 月，百悦泽联合奥妥珠单抗获得FDA加速批准用于治疗R/RFL患者。2025年6月，FDA批准百悦泽的薄膜包衣片剂剂型用于所有已获批适应症。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1428519.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688235","BK4585","BK1583","LU1969619763.USD","LU0588546209.SGD","BK1588","BK4588","BK4526","LU1303224171.USD","LU2328871848.SGD","BK1161","BK4139","LU0307460666.USD","BK1500","LU1719994722.HKD","06160","LU1251922891.USD","LU1770034418.SGD","ONC","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626195663","title":"百济神州安泰适在中国获得上市许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2626195663","media":"南方财经网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626195663?lang=zh_cn&edition=full","pubTime":"2026-04-10 17:26","pubTimestamp":1775813160,"startTime":"0","endTime":"0","summary":"百济神州公司宣布，安泰适?（注射用塔拉妥单抗）经优先审评程序获得国家药品监督管理局（NMPA）附条件批准，用于既往接受过至少2种系统性（包括含铂化疗）失败的广泛期小细胞肺癌（ES-SCLC）成人患者。塔拉妥单抗是首个且目前唯一获批的靶向DLL3和CD3的双特异性T细胞衔接器（TCE）抗体，由百济神州与安进公司（Amgen）共同负责其在中国大陆开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604103701225141.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["688235","BK4139","LU1969619763.USD","BK1588","BK4585","BK1583","LU1770034418.SGD","LU0307460666.USD","LU2328871848.SGD","BK1500","LU1719994722.HKD","LU1303224171.USD","BK1161","ONC","LU1251922891.USD","BK4588","BK0239","IPOS","BK4526","06160","LU0588546209.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625128969","title":"百济神州(06160)授出合共1.77万股美国存托股份受限制股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2625128969","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625128969?lang=zh_cn&edition=full","pubTime":"2026-04-08 17:27","pubTimestamp":1775640476,"startTime":"0","endTime":"0","summary":"百济神州(06160)发布公告，于2026年3月31日，董事会薪酬委员会根据2016期权及激励计划的条款授予154名承授人合共1.77万股美国存托股份受限制股份单位。该等受限制股份单位相当于22.98万股股份，约占本公告之日公司发行股份总数的0.01%。","market":"us","thumbnail":"https://img.zhitongcaijing.com/gonggao/ztcj_announce_23.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/gonggao/ztcj_announce_23.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1426022.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK4139","BK4588","BK1161","LU1719994722.HKD","BK1583","06160","BK1588","BK1500","LU1303224171.USD","ONC","LU1770034418.SGD","BK0239","LU0307460666.USD","688235","LU1969619763.USD","LU0588546209.SGD","BK4585","LU1251922891.USD","LU2328871848.SGD","BK4526"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623138721","title":"每周股票复盘：百济神州（688235）2025年盈利2.87亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2623138721","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623138721?lang=zh_cn&edition=full","pubTime":"2026-03-29 01:27","pubTimestamp":1774718829,"startTime":"0","endTime":"0","summary":"截至2026年3月27日收盘，百济神州报收于232.69元，较上周的227.57元上涨2.25%。本周，百济神州3月27日盘中最高价报235.5元。百济神州当前最新总市值3586.73亿元，在化学制药板块市值排名2/150，在两市A股市值排名35/5191。本周关注点来自业绩披露要点：百济神州2025年实现净利润约2.87亿美元，扭亏为盈。业绩披露要点百济神州公布截至2025年12月31日止年度业绩，总收入约53亿美元，同比增长40.2%；产品收入达53亿美元，同比增长39.8%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032900000164.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1500","LU1719994722.HKD","LU1303224171.USD","LU1969619763.USD","BK1588","BK1161","688235","LU1770034418.SGD","LU2328871848.SGD","LU1251922891.USD","BK1583","BK0239","LU0307460666.USD","06160","LU0588546209.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622675072","title":"百济神州（688235）披露续聘2026年度审计机构公告，3月25日股价下跌0.43%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622675072","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622675072?lang=zh_cn&edition=full","pubTime":"2026-03-25 22:22","pubTimestamp":1774448542,"startTime":"0","endTime":"0","summary":"截至2026年3月25日收盘，百济神州报收于220.17元，较前一交易日下跌0.43%，最新总市值为3393.74亿元。该股当日开盘222.0元，最高226.0元，最低219.37元，成交额达6.81亿元，换手率为2.66%。近日，百济神州有限公司发布《关于续聘2026年度审计机构的公告》。审计委员会已审议同意，并提请董事会及股东大会追认。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032500044020.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1719994722.HKD","LU1770034418.SGD","LU0307460666.USD","BK1583","LU1251922891.USD","LU1969619763.USD","06160","LU2328871848.SGD","BK1500","BK0239","BK1588","LU1303224171.USD","BK1161","688235","LU0588546209.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622206073","title":"百济神州：2025年净利润2.87亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2622206073","media":"每日经济新闻","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622206073?lang=zh_cn&edition=full","pubTime":"2026-03-25 20:10","pubTimestamp":1774440632,"startTime":"0","endTime":"0","summary":"每经AI快讯，3月25日，百济神州公告，2025年收入53.43亿美元，同比增长40.2%；净利润2.87亿美元，上年同期净亏损6.45亿美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603253684282696.html","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603253684282696.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["688235","06160","ONC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621768777","title":"百济神州跌5.30%，浦银国际证券二周前给出“买入”评级，目标价236.00元","url":"https://stock-news.laohu8.com/highlight/detail?id=2621768777","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621768777?lang=zh_cn&edition=full","pubTime":"2026-03-23 16:36","pubTimestamp":1774255005,"startTime":"0","endTime":"0","summary":"今日百济神州跌5.30%，收盘报215.51元。2026年3月9日，浦银国际证券研究员阳景,胡泽宇发布了对百济神州的研报《四季度收入符合预期，2026年催化剂丰富》，该研报对百济神州给出“买入”评级，认为其目标价为236.0元，研报发布时股价为238.49元，预期涨幅为1.04%。证券之星数据中心计算显示，对该股盈利预测较准的分析师团队为中信证券的甘坛焕。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032300025277.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688235","06160","161027"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1777949067773,"stockEarnings":[{"period":"1week","weight":0.002},{"period":"1month","weight":0.0052},{"period":"3month","weight":-0.1531},{"period":"6month","weight":-0.2088},{"period":"1year","weight":-0.101},{"period":"ytd","weight":-0.1258}],"compareEarnings":[{"period":"1week","weight":0.0046},{"period":"1month","weight":0.0566},{"period":"3month","weight":-0.0014},{"period":"6month","weight":0.0398},{"period":"1year","weight":0.2541},{"period":"ytd","weight":0.0361}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"百济神州有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"35235人(较上一季度增加6.53%)","perCapita":"3265股","listingDate":"2021-12-15","address":"c/oBeOneMedicinesIGmbH,Aeschengraben27,4051Basel,Switzerland","registeredCapital":"15万元","survey":" 百济神州有限公司的主营业务是研究、开发、生产以及商业化创新型药物。公司的主要产品是抗肿瘤类药物。","listedPrice":192.6},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"百济神州(688235)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供百济神州(688235)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"百济神州,688235,百济神州股票,百济神州股票老虎,百济神州股票老虎国际,百济神州行情,百济神州股票行情,百济神州股价,百济神州股市,百济神州股票价格,百济神州股票交易,百济神州股票购买,百济神州股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"百济神州(688235)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供百济神州(688235)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}